Welcome to our dedicated page for Milestone Scient news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scient stock.
Milestone Scientific Inc. (MLSS) is described in its public disclosures as a technology-focused medical research and development company that patents, designs and develops computerized injection technologies and instruments for medical, dental and cosmetic applications. The company’s news flow centers on its computerized drug delivery instruments, which are designed to provide painless and precise injections using its DPS Dynamic Pressure Sensing Technology® platform.
News updates commonly cover developments in Milestone Scientific’s dental segment, including expansion of direct sales programs in North America, new international registrations for the STA® Single Tooth Anesthesia System, and initiatives such as The Wand® Ambassador Program. That program uses experienced dental professionals to share real-world clinical insights and workflow considerations to support broader adoption of The Wand STA System.
In the medical segment, news items highlight the CompuFlo® technology and the CompuFlo Epidural System, including growing utilization of CompuFlo disposables, interest from hospitals and international distributors, and progress on reimbursement strategies. Milestone Scientific reports milestones such as Medicare Part B payment-rate assignments under CPT® code 0777T in several jurisdictions and early activity from commercial insurers, which it views as important for adoption in interventional pain management and spine intervention markets.
Other recurring themes in Milestone Scientific’s news include quarterly financial results, cost-management and operational transformation efforts, leadership appointments, board changes, and updates on NYSE American listing compliance matters. Investors and observers can use this news stream to follow the company’s commercial initiatives in dental and medical markets, its reimbursement and payer-access efforts, and its corporate and governance developments over time.
Milestone Scientific (NYSE: MLSS) has been invited to present at the virtual Summer Solstice – Best Ideas from the Buy-Side conference, scheduled for June 1-4, 2021. CEO Arjan Haverhals will present on June 2 at 2:00 PM ET and engage in one-on-one meetings with investors during the event. The presentation can be streamed live and is available for replay. The conference features top buy-side recommendations and aims to showcase innovative companies. Milestone specializes in advanced injection technologies aimed at painless and precise drug delivery.
Milestone Scientific (NYSE: MLSS) reported a robust 61% year-over-year revenue increase to $2.9 million for Q1 2021, aided by a 32% sequential rise from Q4 2020. As of March 31, 2021, the company maintained approximately $17 million in cash. Despite a gross profit margin decline to 62%, they reduced their operating loss to $1.0 million from $1.6 million in the prior year. The company continues to focus on expanding its medical product commercialization, particularly its CompuFlo Epidural System, viewing 2021 as pivotal for growth.
Milestone Scientific (NYSE: MLSS) announced significant leadership changes effective May 19, 2021. Jan Adriaan (Arjan) Haverhals was promoted to CEO, replacing Leonard Osser, who will serve as Vice Chairman of the Board. Scott Kahn was appointed as CFO, succeeding Joseph D’Agostino. Haverhals has been pivotal in sales and marketing strategies, while Kahn brings over 40 years of financial expertise from various sectors. The company aims to strengthen its position in the medical technology market, particularly in pain-free injection systems.
Milestone Scientific (NYSE American: MLSS) will hold a conference call on May 17, 2021, at 11:00 A.M. ET to discuss first-quarter financial results for March 31, 2021. The call can be accessed by U.S. callers at 1-877-407-0778 and international callers at 201-689-8565. A webcast will also be available online. An audio replay will be accessible until May 31, 2021, using the provided access codes. Milestone is known for its innovative drug delivery systems that offer precise and painless injections across various medical applications.
Milestone Scientific (NYSE: MLSS) announced a significant business update, reporting a 61% increase in Q1 2021 revenue to $2.9 million from $1.8 million year-over-year. Sequentially, sales rose 32% from Q4 2020. The company attributes this growth to a successful dental sales strategy and initial revenues from medical disposables, which they see as a transformative opportunity. Milestone’s innovative injection technology continues to position the company favorably in the biomedical market.
Milestone Scientific (MLSS) reported a 78% revenue increase in Q4 2020 compared to Q3, totaling approximately $1 million. Despite the impact of COVID-19, the company managed to reduce its net loss to approximately $(7.3) million or $(0.12 per share. Revenue for 2020 was $5.4 million, down from $8.3 million in 2019. The company is expanding its dental distribution network and has begun commercial efforts with the CompuFlo Epidural Instrument, focusing on high-margin disposable components and positive responses from hospitals. Cash reserves exceed $14 million.
Milestone Scientific Inc. (NYSE American: MLSS) announced a conference call scheduled for April 1, 2021, at 4:30 p.m. ET. The call will address the company's financial results for the year ending December 31, 2020, alongside updates on corporate progress and developments. U.S. callers can dial 1-877-407-0778, while international callers should use 201-689-8565. An audio replay will be accessible until April 15, 2021. The company specializes in computerized drug delivery systems aimed at making injections virtually painless. For further details, visit their website.
Milestone Scientific Inc. (NYSE: MLSS) announces that CEO Arjan Haverhals will present at the Q1 Virtual Investor Summit on March 24, 2021, at 11:00 AM ET. The summit will be held from March 23-25 and connects smallcap and microcap companies to investors. The event features 100 companies and over 300 investors. Milestone Scientific specializes in computerized drug delivery technologies, ensuring precise and virtually painless injections. For registration details, visit www.investorsummitgroup.com.
Milestone Scientific (NYSE American: MLSS) has received a Notice of Allowance from the European Patent Office for its innovative CompuFlo instrument, which combines minimum intensity of nerve stimulation and real-time injection pressure monitoring. This technology aims to improve ultrasound-guided peripheral nerve block (PNB) procedures by enhancing needle tip location and reducing injury risks. Developed in collaboration with experts, this advancement positions Milestone for growth in the PNB market, relevant for surgical and postoperative analgesia, with similar patent applications underway in the U.S.
Milestone Scientific (NYSE American:MLSS) has commenced the sale of its CompuFlo® / CathCheck™ disposables to the Medical University of South Carolina (MUSC), the top-ranked hospital in South Carolina. President Arjan Haverhals highlighted that this follows extensive testing by MUSC's team, reflecting a positive reception of the technologies. The CompuFlo system is noted to decrease epidural punctures and save time for anesthesiologists, while the CathCheck technology enhances catheter placement confirmation efficiency. These innovations may offer economic advantages for healthcare institutions.